Targeted therapy and their ocular complications

Denis Jusufbegovic, L. Pierre, Arun D. Singh

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.

Original languageEnglish (US)
Title of host publicationClinical Ophthalmic Oncology
Subtitle of host publicationBasic Principles and Diagnostic Techniques, Second Edition
PublisherSpringer Berlin Heidelberg
Pages123-132
Number of pages10
ISBN (Electronic)9783642404894
ISBN (Print)9783642404887
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Cytotoxins
Hematologic Neoplasms
Human Activities
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jusufbegovic, D., Pierre, L., & Singh, A. D. (2014). Targeted therapy and their ocular complications. In Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition (pp. 123-132). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-40489-4_13

Targeted therapy and their ocular complications. / Jusufbegovic, Denis; Pierre, L.; Singh, Arun D.

Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. Springer Berlin Heidelberg, 2014. p. 123-132.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jusufbegovic, D, Pierre, L & Singh, AD 2014, Targeted therapy and their ocular complications. in Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. Springer Berlin Heidelberg, pp. 123-132. https://doi.org/10.1007/978-3-642-40489-4_13
Jusufbegovic D, Pierre L, Singh AD. Targeted therapy and their ocular complications. In Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. Springer Berlin Heidelberg. 2014. p. 123-132 https://doi.org/10.1007/978-3-642-40489-4_13
Jusufbegovic, Denis ; Pierre, L. ; Singh, Arun D. / Targeted therapy and their ocular complications. Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition. Springer Berlin Heidelberg, 2014. pp. 123-132
@inbook{2452cf3b362a4a9ba70fb483e5365814,
title = "Targeted therapy and their ocular complications",
abstract = "The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.",
author = "Denis Jusufbegovic and L. Pierre and Singh, {Arun D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-40489-4_13",
language = "English (US)",
isbn = "9783642404887",
pages = "123--132",
booktitle = "Clinical Ophthalmic Oncology",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Targeted therapy and their ocular complications

AU - Jusufbegovic, Denis

AU - Pierre, L.

AU - Singh, Arun D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.

AB - The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.

UR - http://www.scopus.com/inward/record.url?scp=84956758035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956758035&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-40489-4_13

DO - 10.1007/978-3-642-40489-4_13

M3 - Chapter

AN - SCOPUS:84956758035

SN - 9783642404887

SP - 123

EP - 132

BT - Clinical Ophthalmic Oncology

PB - Springer Berlin Heidelberg

ER -